Clinical trial: a randomized controlled study on prevention of variceal rebleeding comparing nadolol plus ligation vs. hepatic venous pressure gradient-guided pharmacological therapy


Por: Villanueva, C, Aracil, C, Colomo, A, Lopez-Balaguer, JM, Piqueras, M, Gonzalez, B, Torras, X, Guarner, C, Balanzo, J

Publicada: 15 feb 2009
Resumen:
Hepatic venous pressure gradient (HVPG) monitoring of therapy to prevent variceal rebleeding provides strong prognostic information. Treatment of nonresponders to beta-blockers +/- nitrates has not been clarified. To assess the value of HVPG-guided therapy using nadolol + prazosin in nonresponders to nadolol + isosorbide-5-mononitrate (ISMN) compared with a control group treated with nadolol + ligation. Cirrhotic patients with variceal bleeding were randomized to HVPG-guided therapy (n = 30) or nadolol + ligation (n = 29). A Baseline haemodynamic study was performed and repeated within 1 month. In the guided-therapy group, nonresponders to nadolol + ISMN received nadolol and carefully titrated prazosin and had a third haemodynamic study. Nadolol + prazosin decreased HVPG in nonresponders to nadolol + ISMN (P < 0.001). Finally, 74% of patients were responders in the guided-therapy group vs. 32% in the nadolol + ligation group (P < 0.01). The probability of rebleeding was lower in responders than in nonresponders in the guided therapy group (P < 0.01), but not in the nadolol + ligation group (P = 0.41). In all, 57% of nonresponders rebled in the guided-therapy group and 20% in the nadolol + ligation group (P = 0.05). The incidence of complications was similar. In patients treated to prevent variceal rebleeding, the association of nadolol and prazosin effectively rescued nonresponders to nadolol and ISMN, improving the haemodynamic response observed in controls receiving nadolol and endoscopic variceal ligation. Our results also suggest that ligation may rescue nonresponders.

Filiaciones:
Villanueva, C:
 Autonomous Univ Barcelona, Hosp Santa Crue & St Pau, Serv Patol Digest, Dept Gastroenterol,Gastrointestinal Bleeding Unit, Barcelona 08025, Spain

 CIBEREHD, Madrid, Spain

Colomo, A:
 CIBEREHD, Madrid, Spain

Torras, X:
 CIBEREHD, Madrid, Spain

Guarner, C:
 CIBEREHD, Madrid, Spain

Balanzo, J:
 CIBEREHD, Madrid, Spain
ISSN: 02692813





ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Editorial
WILEY, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Reino Unido
Tipo de documento: Article
Volumen: 29 Número: 4
Páginas: 397-408
WOS Id: 000262314900005
ID de PubMed: 19006538

MÉTRICAS